LRRK2 and synucleinopathy: Other approaches focus on targeting various genes or proteins associated with alpha-synucleinopathies, such as glucocerebrosidase, LRRK2, and poly(ADP-ribose) polymerase-1 (PARP-1) [56–60], or directly target α-syn aggregation using small molecules like Anle138b [61].